EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Jubilant Pharmova Limited (JUBLPHARMA) fair value: what the stock is really worth

As of Oct 1, 2026: fair value of Jubilant Pharmova Limited ₹308, price ₹999, upside -69.2%, quality 43 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · IN · ISIN INE700A01033

JP Broad data Oct 2, 2026

Jubilant Pharmova Limited

JUBLPHARMA · NSE

Weakest SetupStrongly overvalued and low quality.

!Fair value ₹308.33 · Strongly overvalued (−69.2%)
!Quality 43/100
!Expensive Growth (revenue 5y +6.3 %/yr)
!Thin margins · 4.1% net margin (TTM)
!Low debt · negative free cash flow
!0.5% dividend yield · Token dividend
!Trails peers (4/14)
!Narrow moat 30/100
!Weak on past: 24 out of 100
!Weak on dividend: 10 out of 100
Watch Jubilant Pharmova Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹1,264 ₹265.76 Fair Value ₹308.33 Jun 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.

How to read this chart

60‑month range ₹265.76 – ₹1,264 · fair‑value band ₹308.33 – ₹319.00 · the ₹999.30 price screens above the ₹308.33 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 2, 2026.

Follow Jubilant Pharmova in your weekly email

Every Wednesday you see whether Jubilant Pharmova is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally.

Show more

Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. Its Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom and allergy immunotherapy products. The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. Its Generics segment engages in the development, manufacturing, distribution, sale, and marketing of generic formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, antibiotics, and multispecialty. The Contract Research Development and Manufacturing Organisation segment offers drug discovery services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment provides patient-focused biopharmaceutical services to address unmet medical needs in oncology and autoimmune diseases. The company serves pharmaceutical, biotech, group purchasing organisations, allergists, and hospitals sectors. It sells its products through a network of dealers and distributors. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is based in Noida, India.

Stock analysis

Jubilant Pharmova Limited (JUBLPHARMA) currently trades at ₹999.30, while our model-based Fair Value estimate is ₹308.33, 69.2% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of ₹553.52 per share, and 1 of the 16 models we run sit above the ₹999.30 price.

Bear case: the Dividend Discount group reads lowest at ₹61.18, and 15 of the 16 models stay below the price. Evidence for this calculation is high.

Scenario range: ₹308.33 (bear) to ₹319.00 (bull), the price of ₹999.30 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Jubilant Pharmova Limited reported revenue of ₹82.8B in FY2026 versus ₹61.3B in FY2022, a compound +7.8%/yr. Reported net income was ₹4.0B in FY2026, compounding −0.9%/yr from FY2022.

Key figures

Market cap ₹159B (≈ $1.6B) · P/E ratio 46.5 · P/S ratio 2.24 · EPS (TTM) ₹21.48 · Dividend yield 0.5% · Net margin 4.8% · Return on equity 6.0% · Return on assets (EBIT) 17.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).

What moves the price

The share trades about 15% below its 52-week high and 25% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −69%, JUBLPHARMA screens richer than that median.

Fair Value models

Bear ₹308.33 Fair Value ₹308.33 Bull ₹319.00
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹8.35 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Residual Income ₹329.20 ₹326.16 ₹342.86 76
EPV ₹196.88 ₹238.40 ₹273.00 74
ROIC Compounder ₹196.88 ₹238.40 ₹273.00 72
All 16 models by family
Earnings-Based
Graham-Dodd ₹171.09 ₹543.18 ₹723.83 64
Lynch FV ₹119.58 ₹170.84 ₹222.09 61
PEG = 1.0 ₹119.58 ₹170.84 ₹222.09 57
EPV ₹196.88 ₹238.40 ₹273.00 74
Dividend Discount
Gordon GGM ₹39.00 ₹70.27 ₹96.74 68
DDM Multi-Stage ₹39.00 ₹61.18 ₹75.07 67
Multiples
P/E Multiple ₹415.14 ₹553.52 ₹691.90 63
P/S Multiple ₹320.79 ₹427.72 ₹534.65 58
P/B Multiple ₹320.79 ₹427.72 ₹534.65 55
EV/EBIT ₹552.02 ₹771.89 ₹991.76 66
EV/EBITDA ₹727.57 ₹1,006 ₹1,284 67
EV/Revenue ₹363.19 ₹564.95 ₹766.71 53
Asset-Based
NCAV (Graham) ₹223.91 ₹300.04 ₹447.81 54
Economic Profit
Residual Income ₹329.20 ₹326.16 ₹342.86 76
ROIC Compounder ₹196.88 ₹238.40 ₹273.00 72
Growth Earnings
Growth-Adj P/E ₹343.93 ₹491.33 ₹638.73 67

Open the full fair value analysis →

Notify me when JUBLPHARMA reaches fair value

Put JUBLPHARMA on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 43/100

Of which business quality 45 · Market factors (momentum, volatility) 55

Profitability 31
Margins and returns on capital today
Quality Growth 33
Are margins and returns improving?
Cashflow 37
Earnings quality: real cash, not paper profit
Fin. Strength 53
Balance sheet, leverage, solvency risk
Investment 36
Disciplined investing over empire-building
Low Volatility 82
Calm price path (market factor)
Momentum 45
Price trend over the last 3–12 months (market factor)
52W Momentum 39
Distance to the 52-week high (market factor)
Net Issuance 82
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+14.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.3%
Start year 2021 (pandemic). Over 10 years: +3.7% a year
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.8%
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−13.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year−13.7%
Dividend (yield on the price)0.5%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−13.7% vs −2.1%, slowing
Profit margin 2004 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.15% → 10%
Start year 2021 (pandemic)

JUBLPHARMA screens overvalued: fair value 69% below the price. Compare with Merck KGaA →

Compare Jubilant Pharmova Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 585 stocks

Beats the industry median on 4/14 measures
Overall it trails its industry peers.
Valuation
Quality Score 43 · Below median
Fair Value upside −69.1% · Bottom 25%
Profitability
Return on equity (TTM) 6.0% · Below median
Return on assets 3.6% · Above median
Net margin (TTM) 4.1% · Below median
Operating margin (TTM) 5.4% · Below median
Growth and dividend
Revenue growth 17.3% · Above median
Dividend yield (TTM) 0.5% · Bottom 25%
Balance sheet
Debt / equity 0.42× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (TTM) 46.5× · Pricier than median
P/B 2.24× · Pricier than median
P/S (TTM) 1.85× · Cheaper than median
EV/EBITDA 16.5× · Pricier than median
PEG 0.14× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 14
FUTURE (revenue growth)87 · sector 24
PAST (return on equity)24 · sector 28
HEALTH (low debt)79 · sector 96
DIVIDEND (yield)10 · sector 31

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €134.45 €108.94 −19%
Takeda Pharmaceutical Company TAK $18.90 $11.45 −39%
Teva Pharmaceutical Industries Limited TEVA $39.19 $20.88 −47%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,852 ₹1,979 +7%
Galderma Group GALD CHF 163.00 CHF 110.32 −32%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥44.86 ¥49.35 +10%
Haleon plc HLN $9.26 $8.49 −8%
Sandoz Group SDZ CHF 71.16 CHF 40.32 −43%
Zoetis Inc ZTS $70.30 $110.50 +57%
Divi's Laboratories Limited DIVISLAB ₹9,620 ₹1,871 −81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Jubilant Pharmova Limited · Fair Value
₹308.33 −69%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Jubilant Pharmova Limited Fair Value". https://www.fairvalue-calculator.com/stock/JUBLPHARMA

Frequently asked questions

Is Jubilant Pharmova Limited (JUBLPHARMA) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of ₹308.33 versus a price of ₹999.30, about −69% upside (overvalued).
What is the fair value of JUBLPHARMA?
Our model-based fair value for Jubilant Pharmova Limited is ₹308.33 (as of Oct 2, 2026), built from audited fundamentals. The current price: ₹999.30.
What is the quality score of JUBLPHARMA?
Jubilant Pharmova Limited has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Jubilant Pharmova Limited (JUBLPHARMA)?
Our model-based price target is the fair value of ₹308.33 (as of Oct 2, 2026) from 16 valuation models. Cautious scenario ₹308.33, optimistic scenario ₹319.00. It is a calculation from audited fundamentals, not an analyst target.
What is the Jubilant Pharmova Limited stock forecast for 2026?
Our models put fair value at ₹308.33, about −69% upside versus a price of ₹999.30 (overvalued). Cautious scenario ₹308.33, optimistic scenario ₹319.00. The calculation is refreshed regularly with new filings.
What is the revenue of Jubilant Pharmova Limited (JUBLPHARMA)?
Jubilant Pharmova Limited reported trailing-twelve-month revenue of about ₹86.1B (latest available figure, as of Oct 2, 2026).
Does Jubilant Pharmova Limited pay a dividend?
Jubilant Pharmova Limited currently shows a dividend yield of about 0.50% relative to its recent price (as of Oct 2, 2026).
What is the intrinsic value of Jubilant Pharmova Limited (JUBLPHARMA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Jubilant Pharmova Limited it is ₹308.33 per share (as of Oct 2, 2026), against a price of ₹999.30. It is the blended result of 16 valuation models (cash flow, earnings, asset, dividend).
Is Jubilant Pharmova Limited stock overvalued or undervalued in 2026?
As of Oct 2, 2026, JUBLPHARMA trades above its calculated fair value: price ₹999.30, fair value ₹308.33, a gap of about −69% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of JUBLPHARMA?
No. The price is what the market pays today (₹999.30); the fair value is what the company's own numbers justify (₹308.33). For Jubilant Pharmova Limited the two are ₹690.97 per share apart. That gap is exactly why we show both numbers side by side.
How much is Jubilant Pharmova Limited worth?
The market values Jubilant Pharmova Limited at about ₹159B (market capitalisation, as of Oct 2, 2026). Per share that is ₹999.30; our models calculate a fair value of ₹308.33 per share.
What do the bullish and bearish scenarios say about JUBLPHARMA?
Our models span a range for Jubilant Pharmova Limited: cautious scenario ₹308.33, base ₹308.33, optimistic ₹319.00 per share (as of Oct 2, 2026, price ₹999.30). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of JUBLPHARMA?
Jubilant Pharmova Limited trades at a price-to-earnings ratio of 46.5 (as of Oct 2, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹308.33 is built from several models across several years. Other multiples: PEG 0.1, P/B 2.2, P/S 1.8, EV/EBITDA 16.5.
What is the PEG ratio of JUBLPHARMA?
The PEG ratio of Jubilant Pharmova Limited is 0.14 (P/E divided by earnings growth, as of Oct 2, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Jubilant Pharmova Limited (JUBLPHARMA)?
Balance-sheet figures for Jubilant Pharmova Limited (as of Oct 2, 2026): return on equity 6.0%, debt of 0.42 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is JUBLPHARMA from its 52-week high?
Jubilant Pharmova Limited trades at ₹999.30, about 15% below its 52-week high of ₹1,177 and 25% above the low of ₹802.00 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹308.33 is for.
Which stocks are comparable to Jubilant Pharmova Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Jubilant Pharmova Limited stock attractive at the current price?
The data as of Oct 2, 2026: price ₹999.30, calculated fair value ₹308.33 (−69%), Quality Score 43/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of JUBLPHARMA calculated?
We run Jubilant Pharmova Limited through 16 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹308.33, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Jubilant Pharmova Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Jubilant Pharmova Limited (JUBLPHARMA)?
The closing price on Oct 1, 2026 was ₹999.30. Our model-based fair value is ₹308.33, about −69% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Jubilant Pharmova Limited right now?
The price sits above even our optimistic bull case (₹319.00). The favourable scenario is already priced in. Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts. The models converge in a tight band (₹308.33 to ₹319.00), unusually little disagreement for a valuation.
Where does the earnings growth of Jubilant Pharmova Limited (JUBLPHARMA) come from?
Earnings per share at Jubilant Pharmova Limited grew −1.4 % a year from 2016 to 2026. Broken into its drivers: revenue per share +2.7 %, EBIT margin −6.9 %, tax rate −0.2 %, residual (interest, one-offs) +3.4 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Jubilant Pharmova Limited

How large is the market capitalisation of Jubilant Pharmova Limited (JUBLPHARMA)?
The market capitalisation of Jubilant Pharmova Limited is ₹159B (≈ $1.6B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Jubilant Pharmova Limited (JUBLPHARMA)?
The price-to-sales ratio of Jubilant Pharmova Limited is 2.24 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Jubilant Pharmova Limited (JUBLPHARMA)?
Earnings per share at Jubilant Pharmova Limited are ₹21.48 (price ÷ EPS = P/E 46.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Jubilant Pharmova Limited (JUBLPHARMA)?
The dividend yield of Jubilant Pharmova Limited is 0.5% (payout 23.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Jubilant Pharmova Limited (JUBLPHARMA)?
The net margin of Jubilant Pharmova Limited is 4.8% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Jubilant Pharmova Limited (JUBLPHARMA)?
The return on equity (ROE) of Jubilant Pharmova Limited is 6.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Jubilant Pharmova Limited (JUBLPHARMA)?
On an EBIT basis the return on assets of Jubilant Pharmova Limited is 17.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Jubilant Pharmova Limited (JUBLPHARMA)?
The operating margin of Jubilant Pharmova Limited is 5.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Jubilant Pharmova Limited (JUBLPHARMA)?
Revenue at Jubilant Pharmova Limited is growing +17.3% versus a year earlier (3y avg +9.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Jubilant Pharmova Limited (JUBLPHARMA)?
Earnings per share at Jubilant Pharmova Limited are growing −45.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Jubilant Pharmova Limited (JUBLPHARMA) generate?
The free cash flow of Jubilant Pharmova Limited is −₹4.4B (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Jubilant Pharmova Limited (JUBLPHARMA) carry?
The net debt of Jubilant Pharmova Limited is ₹23.5B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Jubilant Pharmova Limited in the live analysis

One click puts Jubilant Pharmova Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.